Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03356860
Title Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Grand Hopital de Charleroi

breast medullary carcinoma

invasive lobular carcinoma

triple-receptor negative breast cancer

invasive ductal carcinoma

Her2-receptor negative breast cancer


Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel

Cyclophosphamide + Epirubicin + Paclitaxel

Age Groups: adult | senior
Covered Countries BEL

No variant requirements are available.